Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 1253-1258

  Doesch, Andreas O ^a   Mueller, Susanne ^a   Akyol, Ceylan ^a   Erbel, Christian ^a   Frankenstein, Lutz ^a   Ruhparwar, Arjang ^a   Ehlermann, Philipp ^a   Dengler, Thomas J ^b   Katus, Hugo A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SLK Kliniken Heilbronn   (Germany)

Author keywords

Heart transplant; Immunosuppression; Long term adherence; Modified release tacrolimus

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; BASEL ASSESSMENT OF ADHERENCE WITH IMMUNOSUPPRESSIVE MEDICATION SCALE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEART TRANSPLANTATION; HEMATOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; QUESTIONNAIRE; SCORING SYSTEM; SELF REPORT; TREATMENT REFUSAL; VISUAL ANALOG SCALE;

HEART TRANSPLANT; IMMUNOSUPPRESSION; LONG-TERM ADHERENCE; MODIFIED-RELEASE TACROLIMUS;

ADULT; CALCINEURIN; CYCLOSPORINE; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; TACROLIMUS; TIME FACTORS;

EID: 84885969688     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S52820     Document Type: Article

References (19)

1. Abecassis MM, Seifeldin R, Riordan ME. Patient outcomes and economics of once-daily tacrolimus in renal transplant patients: results of a modeling analysis. Transplant Proc. 2008;40(5):1443-1445.
2. Alloway R, Steinberg S, Khalil K, et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc. 2005;37(2):867-870.
3. Alloway R, Steinberg S, Khalil K, et al. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation. 2007;83(12):1648-1651.
4. Diez Ojea B, Alonso Alvarez M, Aguado Fernández S, Baños Gallardo M, García Melendreras S, Gómez Huertas E. Three-month experience with tacrolimus once-daily regimen in stable renal allografts. Transplant Proc. 2009;41(6):2323-2325.
5. First MR, Fitzsimmons WE. Modified release tacrolimus. Yonsei Med J. 2004;45(6):1127-1131.
6. Florman S, Alloway R, Kalayoglu M, et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc. 2005;37(2):1211-1213.
7. Florman S, Alloway R, Kalayoglu M, et al. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation. 2007;83(12):1639-1642.
8. Heffron TG, Pescovitz MD, Florman S, et al. Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. Am J Transplant. 2007;7(6):1609-1615.
9. Silva HT, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant. 2007;7(3): 595-608.
10. Gasparyan AY, Ayvazyan L, Cocco G, Kitas GD. Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. Curr Pharm Des. 2012;18(11):1543-1555.
11. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-1310.
12. Doesch AO, Mueller S, Konstandin M, et al. Increased adherence after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation: a pre-experimental study. Transplant Proc. 2010;42(10):4238-4242.
13. De Geest S, Abraham I, Dunbar-Jacob J. Measuring transplant patients' compliance with immunosuppressive therapy. West J Nurs Res. 1996;18(5):595-605.
14. Dobbels F, Berben L, De Geest S, et al; Transplant 360 Task Force. The psychometric properties and practicability of self-report instruments to identify medication nonadherence in adult transplant patients: a systematic review. Transplantation. 2010;90(2):205-219.
15. Glass TR, De Geest S, Hirschel B, et al; Swiss HIV Cohort Study. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther (Lond). 2008;13(1):77-85.
16. Deschamps AE, De Geest S, Vandamme AM, Bobbaers H, Peetermans WE, Van Wijngaerden E. Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. AIDS Patient Care STDS. 2008;22(9):735-743.
17. Kofler S, Bigdeli AK, Kaczmarek I, et al. Long-term outcomes after 1000 heart transplantations in six different eras of innovation in a single center. Transpl Int. 2009;22(12):1140-1150.
18. Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. Clin Ther. 2006;28(6):893-905.
19. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;(2):CD000011.